OncoMatch/Clinical Trials/NCT06363825
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Is NCT06363825 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies camrelizumab for advanced hepatocellular carcinoma.
Treatment: camrelizumab — To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage ⅡA, ⅡB, ⅢA, ⅢB (CNLC)
CNLC was divided into stages Ⅱa-Ⅲb
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: targeted therapy
Previous use of targeted drugs, any component of PD-1 MAB or other similar tests
Cannot have received: PD-1 monoclonal antibody
Previous use of ... any component of PD-1 MAB or other similar tests
Cannot have received: systemic therapy
Have not received systematic treatment before
Cannot have received: local treatment
Exception: allowed if >1 month prior to enrollment
Received local treatment (such as surgical resection, radiation therapy, ablative therapy, interventional therapy, etc.) within the past 1 month
Lab requirements
Blood counts
Hemoglobin ≥100g/L; WBC ≥3×10^9/L; ANC ≥1.5×10^9/L; Platelet ≥50×10^9/L
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
Child-Pugh classification grade A or B (5-8 points); Bilirubin <1.5x ULN; ALT and AST <5x ULN
Cardiac function
No severe cardiac failure; LVEF ≥50%; No grade II or above myocardial ischemia or infarction; No poorly controlled arrhythmias (QTc <450 ms men, <470 ms women); NYHA <III
The Child-Pugh classification of liver function is grade A or B (5-8 points); Bilirubin (BIL)<1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase AST<5ULN; Serum creatinine (Cr) ≤1.5ULN; Hemoglobin (HB) ≥100g/L; White blood cell count (WBC)≥3×10^9/L; Absolute neutrophil count (ANC)≥1.5×10^9/L; Platelet (PLT)≥50×10^9/L; Previous serious cardiovascular disease, including but not limited to the following diseases: Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms in men and ≥470 ms in women); According to NYHA criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) < 50% indicated by cardiac color ultrasound
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify